Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tumor-penetrating microparticles
- Development stage
- Preclinical
- Lead developer
- Optimum Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intraperitoneal
01
Overview
Tumor-penetrating microparticles (TPM) is a paclitaxel-loaded microparticle drug-delivery platform developed by Optimum Therapeutics, LLC. The technology utilizes a PLGA (poly(lactic-co-glycolic acid)) copolymer to deliver fractionated dosing designed to 'prime' the tumor microenvironment. The platform consists of two distinct microparticle types: a rapid-release 'Priming TPM' that facilitates interstitial transport and a slow-release 'Sustaining TPM' that provides prolonged antitumor activity. This dual-action approach is intended to improve drug penetration into the deep layers of solid tumors and peritoneal metastases, overcoming the physical barriers of the tumor stroma.
- Other names
- tumor-priming microparticlespaclitaxel-loaded microparticles
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Tumor-penetrating microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-penetrating microparticles.